An international multi-centre, randomised, double-blind, placebo controlled trial to evaluate the efficacy and safety of 0.5% and 2% Pro 2000/5 gels for the prevention of vaginally acquired human immunodeficiency virus (HIV) infections

Submission date 03/05/2005

Recruitment statusNo longer recruiting

Registration date 06/07/2005

Overall study status

Completed

Last Edited 14/03/2017

Condition category

Infections and Infestations

[X] Prospectively registered

[X] Protocol

Statistical analysis plan

[X] Results

Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Sheena McCormack

Contact details

MRC Clinical Trials Unit 222 Euston Rd London United Kingdom NW1 2DA

Additional identifiers

ClinicalTrials.gov (NCT) NCT00262106

Protocol serial number

Study information

Scientific Title

An international multi-centre, randomised, double-blind, placebo controlled trial to evaluate the efficacy and safety of 0.5% and 2% Pro 2000/5 gels for the prevention of vaginally acquired human immunodeficiency virus (HIV) infections

Acronym

MDP301

Study objectives

Null Hypothesis: That there is no difference in aquisition of HIV and sexually transmitted infections (STIs) in women using Pro2000 and placebo gel.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

International multi-centre randomised double-blind placebo-controlled trial

Primary study design

Interventional

Study type(s)

Prevention

Health condition(s) or problem(s) studied

HIV

Interventions

Pro 2000/5 (P) 0.5% and 2% gels, Placebo gel

Intervention Type

Drug

Phase

Not Applicable

Primary outcome(s)

- 1. Acquisition of HIV infection before or at the 9 month time point, confirmed by a Central Reference Laboratory, in participants confirmed to be HIV negative at enrolment
- 2. Grade 3 (severe) or 4 (life-threatening) clinical events noted through systematically solicited questions, or laboratory adverse events confirmed on examination or repeat testing respectively

Key secondary outcome(s))

- 1. Acquisition of HIV infection before or at the 6 and 12 month time points, confirmed by a Central Reference Laboratory, in participants confirmed to be HIV negative at enrolment
- 2. Acquisition of herpes simplex virus type 2 (HSV-2) in women uninfected at enrolment
- 3. The point prevalence of Neisseria gonorrhoeae (NG) or Chlamydia trachomatis (CT) after 24 weeks of follow-up, determined by a positive nucleic acid amplification assay
- 4. All systematically solicited genital adverse events
- 5. All clinical and laboratory adverse events

Completion date

31/03/2009

Eligibility

Key inclusion criteria

- 1. Sexually active
- 2. HIV-negative healthy women
- 3. Not pregnant

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

- 1. Unable or unwilling to provide a reliable method of contact for the field team
- 2. Likely to move permanently out of the area within the next year
- 3. Likely to have sex more than 14 times a week on a regular basis during the course of follow-up
- 4. Using spermicides regularly
- 5. Pregnant or within 6 weeks postpartum at enrolment
- 6. Has grade 3 clinical or laboratory abnormalities which are considered by the clinician or the Trial Management Group to make enrolment inadvisable
- 7. Requiring referral for assessment of a clinically suspicious cervical lesion
- 8. Treatment to the cervix, or to the womb through the cervix, within 30 days of enrolment
- 9. Known latex allergy
- 10. Participating, or having participated within 30 days of enrolment, in a clinical trial of an unlicensed product, microbicide, barrier method or any other intervention likely to impact on the outcome of this trial
- 11. Considered unlikely to be able to comply with the protocol

Date of first enrolment

01/08/2005

Date of final enrolment

Locations

Countries of recruitment

United Kingdom

England

South Africa

Tanzania

Uganda

Zambia

Study participating centre MRC Clinical Trials Unit London United Kingdom NW1 2DA

Sponsor information

Organisation

Medical Research Council (MRC) (UK)

ROR

https://ror.org/03x94j517

Funder(s)

Funder type

Government

Funder Name

Department for International Development

Alternative Name(s)

Department for International Development, UK, DFID

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient- facing?
Results article	results	09/10/2009)	Yes	No
Results article	informed consent results	13/06/2010)	Yes	No
Results article	vaginal gel results	16/10/2010)	Yes	No
Results article	participant response results	21/01/2011		Yes	No
Results article	substudy HIV-1 testing algorithm results	01/01/2012	2	Yes	No
Results article	results	01/02/2013	3	Yes	No
Results article	results	01/03/2015	5	Yes	No
Results article	results	01/05/2015	5	Yes	No
Results article	results	01/01/2016	5	Yes	No
Results article	results	01/01/2016	i i	Yes	No
Results article	HSV-2 results	12/12/2016	5	Yes	No
Results article	results	11/03/2017	,	Yes	No
<u>Protocol article</u>	protocol	27/10/2009)	Yes	No
Other publications	effects of injectable hormonal contraceptives	28/01/2012	2	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11 /2025	No	Yes
Study website	Study website	11/11/2025	-	No	Yes